Dr. Roy Herbst on Antibodies Used Against EGFR Alongside Chemotherapy
Dr. Roy S. Herbst discusses a 5 year study focusing on the use of antibodies against EGFR alongside chemotherapy treatments.
Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses a 5 year study focusing on the use of antibodies against EGFR alongside chemotherapy treatments.
Herbst says that the approach differs from the use of small molecules and was most effective in patients with an increased copy number of the EGFR gene, specifically those with more than four copies of the gene. He says the extra genes discovered in patients were through the use of fluorescent in situ hybridization (FISH).
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
